Published in J Clin Invest on November 01, 1979
ATP depletion as a consequence of adenosine deaminase inhibition in man. Proc Natl Acad Sci U S A (1980) 1.04
Nucleotide pool imbalance and adenosine deaminase deficiency induce alterations of N-region insertions during V(D)J recombination. J Clin Invest (1999) 0.90
2'-deoxyguanosine toxicity for B and mature T lymphoid cell lines is mediated by guanine ribonucleotide accumulation. J Clin Invest (1984) 0.84
Adenosine deaminase polymorphism. Associations at clinical level suggest a role in cell functions and immune reactions. J Med Genet (1981) 0.82
Deoxyadenosine triphosphate as a mediator of deoxyguanosine toxicity in cultured T lymphoblasts. J Clin Invest (1986) 0.80
"Reverse" carbocyclic fleximers: synthesis of a new class of adenosine deaminase inhibitors. Nucleosides Nucleotides Nucleic Acids (2013) 0.79
Mechanisms of 2'-deoxyguanosine toxicity in mouse T-lymphoma cells with purine nucleoside phosphorylase deficiency and resistance to inhibition of ribonucleotide reductase by dGTP. Biochem J (1990) 0.75
Adenosine-deaminase deficiency in two patients with severely impaired cellular immunity. Lancet (1972) 9.01
Nucleoside-phosphorylase deficiency in a child with severely defective T-cell immunity and normal B-cell immunity. Lancet (1975) 5.15
Lymphospecific toxicity in adenosine deaminase deficiency and purine nucleoside phosphorylase deficiency: possible role of nucleoside kinase(s). Proc Natl Acad Sci U S A (1977) 2.90
A NEW METHOD FOR THE DETERMINATION OF THE BASE COMPOSITION OF RIBONUCLEIC ACID. J Biol Chem (1963) 2.84
Deoxyadenosine triphosphate as a potentially toxic metabolite in adenosine deaminase deficiency. Proc Natl Acad Sci U S A (1978) 2.78
Identification and quantitation of adenine deoxynucleotides in erythrocytes of a patient with adenosine deaminase deficiency and severe combined immunodeficiency. J Biol Chem (1978) 2.56
Effects of thymidine on deoxyribonucleoside triphosphate pools and deoxyribonucleic acid synthesis in Chinese hamster ovary cells. J Biol Chem (1973) 2.23
A role for purine metabolism in the immune response: Adenosine-deaminase activity and deoxyadenosine catabolism. Lancet (1978) 2.15
Purine nucleoside phosphorylase deficiency associated with selective cellular immunodeficiency. N Engl J Med (1977) 2.12
Overproduction of adenine deoxynucleosides and deoxynucletides in adenosine deaminase deficiency with severe combined immunodeficiency disease. J Clin Invest (1978) 2.07
A permeable animal cell preparation for studying macromolecular synthesis. DNA synthesis and the role of deoxyribonucleotides in S phase initiation. Biochemistry (1978) 2.05
Regulation of mammalian deoxyribonucleotide biosynthesis by nucleotides as activators and inhibitors. J Biol Chem (1966) 1.97
Purinogenic immunodeficiency diseases: selective toxicity of deoxyribonucleosides for T cells. Proc Natl Acad Sci U S A (1978) 1.93
Abnormal purine metabolism and purine overproduction in a patient deficient in purine nucleoside phosphorylase. N Engl J Med (1976) 1.91
Deoxyadenosine metabolism and cytotoxicity in cultured mouse T lymphoma cells: a model for immunodeficiency disease. Cell (1978) 1.78
Apparent suicide inactivation of human lymphoblast S-adenosylhomocysteine hydrolase by 2'-deoxyadenosine and adenine arabinoside. A basis for direct toxic effects of analogs of adenosine. J Biol Chem (1979) 1.73
Nucleotide pools of Novikoff rat hepatoma cells growing in suspension culture. I. Kinetics of incorporation of nucleosides into nucleotide pools and pool sizes during growth cycle. J Cell Physiol (1971) 1.71
Hydroxyurea reversal of inhibition and use as a cell-synchronizing agent. J Biol Chem (1967) 1.67
Deoxyguanosine triphosphate as a possible toxic metabolite in the immunodeficiency associated with purine nucleoside phosphorylase deficiency. J Clin Invest (1978) 1.61
Isolation and characterization of purine-nucleoside phosphorylase-deficient T-lymphoma cells and secondary mutants with altered ribonucleotide reductase: genetic model for immunodeficiency disease. Proc Natl Acad Sci U S A (1979) 1.57
Differential sensitivity of human leukemic T cell lines and B cell lines to growth inhibition by deoxyadenosine. J Immunol (1978) 1.40
Properties of deoxythymidine kinase partially purified from animal tumors. J Biol Chem (1965) 1.20
Deoxyguanosine toxicity in a mouse T lymphoma: relationship to purine nucleoside phosphorylase-associated immune dysfunction. Cell (1978) 1.14
Deoxyguanosine toxicity on lymphoid cells as a cause for immunosuppression in purine nucleoside phosphorylase deficiency. Cell (1978) 1.07
Selective severe cellular immunodeficiency. Effect of thymus transplantation and transfer factor administration. Clin Immunol Immunopathol (1976) 1.06
A patient with nucleoside phosphorylase deficiency, selective t-cell deficiency, and autoimmune hemolytic anemia. J Pediatr (1978) 1.02
Deoxyadenosine metabolism and toxicity in cultured L5178Y cells. Cancer Res (1977) 0.93
Isolation of hydroxyurea-resistant CHO cells with altered levels of ribonucleotide reductase. Somatic Cell Genet (1979) 0.90
Cellular immune deficiency with autoimmune hemolytic anemia in purine nucleoside phosphorylase deficiency. Am J Med (1979) 0.87
Impaired defense against vaccinia in a child with T-lymphocyte deficiency associated with inosine phosphorylase defect. J Pediatr (1978) 0.86
Mammalian deoxynucleoside kinases. 3. Deoxyadenosine kinase: inhibition by nucleotides and kinetic studies. J Biol Chem (1971) 0.81
Partial deficiency of purine nucleoside phosphorylase: studies of purine and pyrimidine metabolism. J Lab Clin Med (1978) 0.80
Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc Natl Acad Sci U S A (1994) 8.13
Enzyme defect associated with a sex-linked human neurological disorder and excessive purine synthesis. Science (1967) 7.75
Human beta-defensin-1 is a salt-sensitive antibiotic in lung that is inactivated in cystic fibrosis. Cell (1997) 5.99
Transduction with recombinant adeno-associated virus for gene therapy is limited by leading-strand synthesis. J Virol (1996) 5.94
Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses. J Virol (1995) 5.67
Recombinant adeno-associated virus for muscle directed gene therapy. Nat Med (1997) 4.87
MHC class I-restricted cytotoxic T lymphocytes to viral antigens destroy hepatocytes in mice infected with E1-deleted recombinant adenoviruses. Immunity (1994) 4.65
Gene therapy vectors based on adeno-associated virus type 1. J Virol (1999) 4.63
Successful ex vivo gene therapy directed to liver in a patient with familial hypercholesterolaemia. Nat Genet (1994) 4.33
Submucosal glands are the predominant site of CFTR expression in the human bronchus. Nat Genet (1992) 4.12
The use of proteolytic enzymes to improve immunoglobulin staining by the PAP technique. Histochem J (1979) 4.06
Studies on alcaptonuria: 2. Investigations on a case of human alcaptonuria. Biochem J (1947) 4.03
Stable gene transfer and expression of human blood coagulation factor IX after intramuscular injection of recombinant adeno-associated virus. Proc Natl Acad Sci U S A (1997) 3.84
The peptide antibiotic LL-37/hCAP-18 is expressed in epithelia of the human lung where it has broad antimicrobial activity at the airway surface. Proc Natl Acad Sci U S A (1998) 3.83
Correction of the cystic fibrosis defect in vitro by retrovirus-mediated gene transfer. Cell (1990) 3.70
Inactivation of E2a in recombinant adenoviruses improves the prospect for gene therapy in cystic fibrosis. Nat Genet (1994) 3.56
Human beta-defensin 2 is a salt-sensitive peptide antibiotic expressed in human lung. J Clin Invest (1998) 3.51
Ablation of E2A in recombinant adenoviruses improves transgene persistence and decreases inflammatory response in mouse liver. Proc Natl Acad Sci U S A (1994) 3.38
A specific enzyme defect in gout associated with overproduction of uric acid. Proc Natl Acad Sci U S A (1967) 3.29
Transduction of dendritic cells by DNA viral vectors directs the immune response to transgene products in muscle fibers. J Virol (1998) 3.14
Natural variation in light sensitivity of Arabidopsis. Nat Genet (2001) 2.97
Screening for refractive errors at age 1 year: a pilot study. Br J Ophthalmol (1979) 2.94
Exchange of surface proteins impacts on viral vector cellular specificity and transduction characteristics: the retina as a model. Hum Mol Genet (2001) 2.88
Replication-defective vector based on a chimpanzee adenovirus. J Virol (2001) 2.86
Hypoxanthine-guanine phosphoribosyltransferase deficiency in gout. Ann Intern Med (1969) 2.84
Acute cytokine response to systemic adenoviral vectors in mice is mediated by dendritic cells and macrophages. Mol Ther (2001) 2.83
Screening for visual defects in preschoolchildren. Br J Ophthalmol (1986) 2.82
Efficacy and safety of adeno-associated viral vectors based on serotype 8 and 9 vs. lentiviral vectors for hemophilia B gene therapy. J Thromb Haemost (2006) 2.81
Effect of spectinomycin use on the prevalence of spectinomycin-resistant and of penicillinase-producing Neisseria gonorrhoeae. N Engl J Med (1987) 2.70
Isolation of highly infectious and pure adeno-associated virus type 2 vectors with a single-step gravity-flow column. Hum Gene Ther (2001) 2.69
Direct gene transfer of human CFTR into human bronchial epithelia of xenografts with E1-deleted adenoviruses. Nat Genet (1993) 2.67
A first attempt to prevent amblyopia and squint by spectacle correction of abnormal refractions from age 1 year. Br J Ophthalmol (1985) 2.65
Gene therapy: adenovirus vectors. Curr Opin Genet Dev (1993) 2.61
A possible nucleotide-binding domain in the tertiary fold of phosphoribosyltransferases. J Biol Chem (1983) 2.60
Inefficient gene transfer by adenovirus vector to cystic fibrosis airway epithelia of mice and humans. Nature (1994) 2.57
Recombinant IL-12 prevents formation of blocking IgA antibodies to recombinant adenovirus and allows repeated gene therapy to mouse lung. Nat Med (1995) 2.55
[Principles and practice of mass screening for disease]. Bol Oficina Sanit Panam (1968) 2.54
Activation of innate immunity in nonhuman primates following intraportal administration of adenoviral vectors. Mol Ther (2001) 2.53
A model system for in vivo gene transfer into the central nervous system using an adenoviral vector. Nat Genet (1993) 2.53
The role of adenosine and 2'-deoxyadenosine in mammalian cells. Annu Rev Biochem (1978) 2.49
Anteroapical stunning and left ventricular outflow tract obstruction. Mayo Clin Proc (2001) 2.48
Adenovirus-mediated transfer of the CFTR gene to lung of nonhuman primates: biological efficacy study. Hum Gene Ther (1993) 2.48
The common variant of cystic fibrosis transmembrane conductance regulator is recognized by hsp70 and degraded in a pre-Golgi nonlysosomal compartment. Proc Natl Acad Sci U S A (1993) 2.48
Hybrid vectors based on adeno-associated virus serotypes 2 and 5 for muscle-directed gene transfer. J Virol (2001) 2.46
Immune responses to viral antigens versus transgene product in the elimination of recombinant adenovirus-infected hepatocytes in vivo. Gene Ther (1996) 2.43
Prediction of amblyopia and squint by means of refraction at age 1 year. Br J Ophthalmol (1986) 2.35
Recombinant adenovirus deleted of all viral genes for gene therapy of cystic fibrosis. Virology (1996) 2.35
A replication-defective human adenovirus recombinant serves as a highly efficacious vaccine carrier. Virology (1996) 2.35
Human adenosine deaminase. cDNA and complete primary amino acid sequence. J Biol Chem (1984) 2.33
Upregulation of class I major histocompatibility complex antigens by interferon gamma is necessary for T-cell-mediated elimination of recombinant adenovirus-infected hepatocytes in vivo. Proc Natl Acad Sci U S A (1995) 2.33
CD40 ligand-dependent T cell activation: requirement of B7-CD28 signaling through CD40. Science (1996) 2.21
Sequestration of adenoviral vector by Kupffer cells leads to a nonlinear dose response of transduction in liver. Mol Ther (2001) 2.19
A possible role for kinase-associated protein phosphatase in the Arabidopsis CLAVATA1 signaling pathway. Proc Natl Acad Sci U S A (1997) 2.19
The Silent Gallstone: A Ten to Twenty Year Follow-up Study of 112 Cases. Ann Surg (1948) 2.18
Biology of adenovirus vectors with E1 and E4 deletions for liver-directed gene therapy. J Virol (1996) 2.12
Cell transplantation in liver-directed gene therapy. Cell Transplant (1994) 2.12
Long-term improvement of hypercholesterolemia after ex vivo gene therapy in LDLR-deficient rabbits. Science (1991) 2.11
Current surgical management of congenital diaphragmatic hernia: a report from the Congenital Diaphragmatic Hernia Study Group. J Pediatr Surg (1998) 2.09
Biochemical bases of accelerated purine biosynthesis de novo in human fibroblasts lacking hypoxanthine-guanine phosphoribosyltransferase. J Biol Chem (1968) 2.08
Stable restoration of the sarcoglycan complex in dystrophic muscle perfused with histamine and a recombinant adeno-associated viral vector. Nat Med (1999) 2.07
Adenovirus-mediated transfer of the CFTR gene to lung of nonhuman primates: toxicity study. Hum Gene Ther (1993) 2.07
Expression of alpha v beta 5 integrin is necessary for efficient adenovirus-mediated gene transfer in the human airway. J Virol (1995) 2.05
Purification of recombinant adeno-associated virus vectors by column chromatography and its performance in vivo. Hum Gene Ther (2000) 1.97
Adeno-associated virus as a vector for liver-directed gene therapy. J Virol (1998) 1.94
The innate immune system in cystic fibrosis lung disease. J Clin Invest (1999) 1.93
Purinogenic immunodeficiency diseases: selective toxicity of deoxyribonucleosides for T cells. Proc Natl Acad Sci U S A (1978) 1.93
Benign small bowel tumor. Ann Surg (1975) 1.92
Cathelicidins--a family of multifunctional antimicrobial peptides. Cell Mol Life Sci (2003) 1.89
Stable transgene expression in rod photoreceptors after recombinant adeno-associated virus-mediated gene transfer to monkey retina. Proc Natl Acad Sci U S A (1999) 1.89
Successful adenovirus-mediated gene transfer in an in vivo model of human malignant mesothelioma. Ann Thorac Surg (1994) 1.89
Augmentation of innate host defense by expression of a cathelicidin antimicrobial peptide. Infect Immun (1999) 1.87
Recruitment of wild-type and recombinant adeno-associated virus into adenovirus replication centers. J Virol (1996) 1.86
Inhalation therapy in asthma: nebulizer or pressurized metered-dose inhaler with holding chamber? In vivo comparison of lung deposition in children. J Pediatr (1999) 1.85
Bacterial phosphorylcholine decreases susceptibility to the antimicrobial peptide LL-37/hCAP18 expressed in the upper respiratory tract. Infect Immun (2000) 1.84
Communicating with the dying. J Med Ethics (1975) 1.84
Primary malignancies of the small bowel: a report of 96 cases and review of the literature. Ann Surg (1974) 1.82
Single immunizing dose of recombinant adenovirus efficiently induces CD8+ T cell-mediated protective immunity against malaria. J Immunol (1997) 1.80
Filovirus-pseudotyped lentiviral vector can efficiently and stably transduce airway epithelia in vivo. Nat Biotechnol (2001) 1.80
Clearance of adenovirus-infected hepatocytes by MHC class I-restricted CD4+ CTLs in vivo. J Immunol (1995) 1.75
In vivo correction of low density lipoprotein receptor deficiency in the Watanabe heritable hyperlipidemic rabbit with recombinant adenoviruses. J Biol Chem (1994) 1.71
Molecular basis of defective anion transport in L cells expressing recombinant forms of CFTR. Hum Mol Genet (1993) 1.71
Genotype spectrum of ornithine transcarbamylase deficiency: correlation with the clinical and biochemical phenotype. Am J Med Genet (2000) 1.71
Targeting genes: delivery and persistent expression of a foreign gene driven by mammalian regulatory elements in vivo. J Biol Chem (1989) 1.70
Prolonged transgene expression in cotton rat lung with recombinant adenoviruses defective in E2a. Hum Gene Ther (1994) 1.70
Expression of the cystic fibrosis gene in adult human lung. J Clin Invest (1994) 1.70
Role of viral antigens in destructive cellular immune responses to adenovirus vector-transduced cells in mouse lungs. J Virol (1996) 1.70
High-titer adeno-associated viral vectors from a Rep/Cap cell line and hybrid shuttle virus. Hum Gene Ther (1998) 1.68
Studies on the mechanism of fructose-induced hyperuricemia in man. Metabolism (1972) 1.67
Transcriptional repression by Msx-1 does not require homeodomain DNA-binding sites. Mol Cell Biol (1995) 1.67
Human immunodeficiency virus type 1-specific immune responses in primates upon sequential immunization with adenoviral vaccine carriers of human and simian serotypes. J Virol (2004) 1.66
Regulation of manganese superoxide dismutase by lipopolysaccharide, interleukin-1, and tumor necrosis factor. Role in the acute inflammatory response. J Biol Chem (1990) 1.65
Human hypoxanthine-guanine phosphoribosyltransferase. Demonstration of structural variants in lymphoblastoid cells derived from patients with a deficiency of the enzyme. J Clin Invest (1982) 1.65
Immunology of gene therapy with adenoviral vectors in mouse skeletal muscle. Hum Mol Genet (1996) 1.60
Mouse beta-defensin 1 is a salt-sensitive antimicrobial peptide present in epithelia of the lung and urogenital tract. Infect Immun (1998) 1.59